

DAFTAR PUSTAKA

- Ashariati, A. (2019). Manajemen Kanker Payudara Komprehensif. *J. Chem. Inf. Model.* 53 : 1689–1699.
- Baselga, J., Gelmon, K.A., Verma, S., Wardley, A., Conte, P.F., Miles, D., *et al.* (2010). Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. *J. Clin. Oncol.* 28 : 1138–1144.
- Breast, E., & Trialists, C. (n.d.). Trastuzumab for early-stage, HER2-positive breast cancer : a meta-analysis of 13 864 women in seven randomised trials 1139–1150.
- Comprehensive Cancer Network, N. (n.d.). NCCN Guidelines for Patients:
- Daniels, B., Kiely, B.E., Houssami, N., Lord, S.J., Dobbins, T., Lu, C.Y., *et al.* (2017). Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo) adjuvant trastuzumab : a national population-based observational study (2006 – 2014). *Nat. Publ. Gr.* 118 : 441–447.
- Dawood, S., Broglio, K., Buzdar, A.U., Hortobagyi, G.N., & Giordano, S.H. (2009). Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review. *J. Clin. Oncol.* 28 : 92.
- De, P., Hasmann, M., & Leyland-Jones, B. (2013). Molecular determinants of trastuzumab efficacy: What is their clinical relevance? *Cancer Treat. Rev.* 39 : 925–934.
- Feldman, A.M., Lorell, B.H., & Reis, S.E. (2000). Trastuzumab in the Treatment of Metastatic Breast Cancer. *Circulation* 102 : 272–274.
- Findlay, V.J., & Scholar, E. (2024). Trastuzumab. *xPharm Compr. Pharmacol. Ref.* 1–5.
- Health, A.J.-I.J.C.M.P., & 2018, undefined (2018). Breast cancer screening and diagnosis: a glance back and a look forward. *Res. JavaeedInt. J. Community Med. Public Heal.* 2018•*researchgate.net* 5 : 4997.
- Hilmi, R.Z., Hurriyati, R., & Lisnawati (2018). Keputusan Menteri Kesehatan Republik Indonesia Nomor Hk.01.07/Menkes/414/2018 Tentang Pedoman

Nasional Pelayanan Kedokteran Tata Laksana Kanker Payudara : 91–102.

Ketut, S., Made, S.L., & Kartika, K. (2022). Kanker Payudara: Diagnostik, Faktor Risiko, Dan Stadium. *Ganesha Med.* 2 : 42–48.

Lee, Y., Lee, M., Kim, H., Kim, J., Ahn, J.S., Im, Y., *et al.* (2022). Real-World Evidence of Trastuzumab , Pertuzumab , and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer 54 : 1130–1137.

Lukas Robertus, J., Brompton, R., S Muthanna, F.M., & Shahid Iqbal, M. (n.d.). Cross-cultural adaptation and psychometric properties of the Indonesian version for quality of life among breast cancer patients.

Marzorati, C., Voskanyan, V., Sala, D., Grasso, R., Borgogni, F., Pietrobon, R., *et al.* (2025). Psychosocial factors associated with quality of life in cancer patients undergoing treatment: an umbrella review. *Health Qual. Life Outcomes* 23.

Maximiano, S., Magalhães, P., Guerreiro, M.P., & Morgado, M. (2016). Trastuzumab in the Treatment of Breast Cancer. *BioDrugs* 30 : 75–86.

McDonald, E.S., Clark, A.S., Tchou, J., Zhang, P., & Freedman, G.M. (2016). Clinical Diagnosis and Management of Breast Cancer. *J Nucl Med* 57 : 9–16.

Menkes (2023). Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/Menkes/2197/2023 Tentang Formularium Nasional. *Kementeri. Kesehat. Indones.* 1–219.

Mitsogianni, M., Trontzas, I.P., Gomatou, G., Ioannou, S., Syrigos, N.K., & Kotteas, E.A. (2021). The changing treatment of metastatic her2 - positive breast cancer (Review) 1–10.

Nematollahi, S., Mohammad, S., & Ayatollahi, T. (2012). A comparison of breast cancer survival among young , middle-aged , and elderly patients in southern Iran using Cox and empirical Bayesian additive hazard models 1–7.

Piccart-Gebhart, M.J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., *et al.* (2005). Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. *N. Engl. J. Med.* 353 : 1659–1672.

Picot, J., Cooper, K., Bryant, J., & Clegg, A. (2011). Karnofsky performance status and WHO performance status scores.

quality center, laboratory (n.d.). Human Epidermal Growth Factor Receptor 2 Testing In Breast Cancer: American Society Of Clinical Oncology/College Of

American Pathologists Clinical Practice Guideline Focused Update Topic Recommendation Evidence Rating and Comment.

Rooijen, V., Johan, M., Munck, D., Guusje, M., Graaf, D., Jacques, C., *et al.* (2025). Use of trastuzumab for HER2-positive metastatic breast cancer in daily practice : a population-based study focusing on the elderly 7–12.

Ross, J.S., & Fletcher, J.A. (1998). The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. *Stem Cells* 16 : 413–428.

Rossi, M., Carioli, G., Bonifazi, M., Zambelli, A., Franchi, M., Moja, L., *et al.* (2016). ScienceDirect Trastuzumab for HER2 þ metastatic breast cancer in clinical practice : Cardiotoxicity and overall survival 52 : 39014525.

Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J., Schneeweiss, A., Heeson, S., *et al.* (2015). Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer.

Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., *et al.* (2011). Adjuvant Trastuzumab in HER2-Positive Breast Cancer. *n engl j med* 14 : 1273–83.

Society, A., Oncology, C., & Pathologists, A. (2018). ASCO Guidelines HER2 updates summary 2 : 1–6.

Takahashi, M., Ohtani, S., Nagai, S.E., Takashima, S., & Yamaguchi, M. (2021). The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first - line therapy in Japanese patients with inoperable or recurrent HER2 - positive breast cancer : the COMACHI study. *Breast Cancer Res. Treat.* 185 : 125–134.

Vaccarella, S., Lortet-Tieulent, J., Saracci, R., Conway, D.I., Straif, K., & Wild, C.P. (n.d.). Reducing Social Inequalities In Cancer: Evidence And Priorities For Research.

View of Peningkatan Pengetahuan Kanker Payudara dan Ketrampilan Periksa Payudara Sendiri (SADARI) untuk Deteksi Dini Kanker Payudara di Semutan Jatimulyo Dlingo [WWW Document] (n.d.). URL <https://journal.uui.ac.id/JAMALI/article/view/17847/11185> (diakses 5.30.25).

von Arx, C., De Placido, P., Caltavitturo, A., Di Rienzo, R., Buonaiuto, R., De Laurentiis, M., *et al.* (2023). The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer. *Cancer Treat. Rev.* 113.



UNIVERSITAS
GADJAH MADA

Analisis Kelangsungan Hidup Pasien Kanker Payudara Stadium Metastasis Dengan HER2 Positif Pada Peserta Program Jaminan Kesehatan yang Mendapatkan Terapi Trastuzumab 8 Siklus: Studi Kohort Retrospektif Tahun 2014â€“2025

Mokhamad Cucu Zakaria, Prof. Dr. Erna Kristin , Apt., M.Si.; dr. Rizki Tsalatshita Khair Mahardya, MPH.

Universitas Gadjah Mada, 2026 | Diunduh dari <http://etd.repository.ugm.ac.id/>